The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. by Parikh, SR et al.
Journal of Infection 81 (2020) 4 83–4 98 
Contents lists available at ScienceDirect 
Journal of Infection 
journal homepage: www.elsevier.com/locate/jinf 
Review 
The everchanging epidemiology of meningococcal disease worldwide 
and the potential for prevention through vaccination 
Sydel R. Parikh a , Helen Campbell a , Julie A. Bettinger b , Lee H. Harrison c , Helen S Marshall d , 
Federico Martinon-Torres e , Marco Aurelio Safadi, MD, PhD f , Zhujun Shao g , Bingqing Zhu g , 
Anne von Gottberg h , Ray Borrow i , Mary E Ramsay a , Shamez N Ladhani a , j , ∗
a Immunisation and Countermeasures Division, Public Health England, 61 Colindale Avenue, London, UK 
b Vaccine Evaluation Center, BC Children’s Hospital, University of British Columbia, Vancouver, British Columbia, Canada 
c Infectious Diseases Epidemiology Research Unit, University of Pittsburgh, Pittsburgh, Pennsylvania, USA 
d Robinson Research Institute and Adelaide Medical School, The University of Adelaide and Women’s and Children’s Health Network, Adelaide, South 
Australia 
e Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Hospital Clínico Universitario and Universidad de Santiago de Compostela 
(USC), Galicia, Spain 
f Department of Pediatrics, Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil 
g State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for 
Disease Control and Prevention, Beijing, China. 
h Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South 
Africa 
i Meningococcal Reference Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom. 
j Paediatric Infectious Diseases Research Group (PIDRG), St. George’s University of London, Cranmer Terrace, London SW17 0RE, UK 
a r t i c l e i n f o 
Article history: 
Accepted 31 May 2020 
Available online 3 June 2020 
s u m m a r y 
Neisseria meningitidis is a major cause of bacterial meningitis and septicaemia worldwide and is associ- 
ated with high case fatality rates and serious life-long complications among survivors. Twelve serogroups 
are recognised, of which six (A, B, C, W, X and Y) are responsible for nearly all cases of invasive meningo- 
coccal disease (IMD). The incidence of IMD and responsible serogroups vary widely both geographi- 
cally and over time. For the first time, effective vaccines against all these serogroups are available or 
nearing licensure. Over the past two decades, IMD incidence has been declining across most parts of 
the world through a combination of successful meningococcal immunisation programmes and secular 
trends. The introduction of meningococcal C conjugate vaccines in the early 20 0 0s was associated with 
rapid declines in meningococcal C disease, whilst implementation of a meningococcal A conjugate vac- 
cine across the African meningitis belt led to near-elimination of meningococcal A disease. Consequently, 
other serogroups have become more important causes of IMD. In particular, the emergence of a hypervir- 
ulent meningococcal group W clone has led many countries to shift from monovalent meningococcal C to 
quadrivalent ACWY conjugate vaccines in their national immunisation programmes. Additionally, the re- 
cent licensure of two protein-based, broad-spectrum meningococcal B vaccines finally provides protection 
against the most common group responsible for childhood IMD across Europe and Australia. This review 
describes global IMD epidemiology across each continent and trends over time, the serogroups responsi- 
ble for IMD, the impact of meningococcal immunisation programmes and future needs to eliminate this 
devastating disease. 
Crown Copyright © 2020 Published by Elsevier Ltd on behalf of The British Infection Association. 
This is an open access article under the CC BY-NC-ND license. 
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Invasive meningococcal disease (IMD) is known for its rapid
nset and poor outcomes, with case fatality rates reaching up to
0% in untreated cases and ranging from 4-20.0% with appropri-
te treatment. 1 More than a third of survivors of IMD also experi-ection Association. This is an open access article under the CC BY-NC-ND license. 
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Table 1 
Currently licensed and available polysaccharide-conjugate and broad-spectrum meningococcal vaccines 
Vaccine Coverage ( N. meningitidis serogroup) Manufacturer Protein conjugate 
Protein conjugate vaccines 
Meningitec R © C Nuron Biotech Inc., Exton, PA, USA CRM197 
Menjugate R © C GlaxoSmithKline Biologicals SA, Rixensart Belgium CRM197 
NeisVac-C R © C Pfizer Inc., New York, NY, USA Tetanus toxoid 
MenAfriVac R © A Serum Institute of India Ltd., Pune, India Tetanus toxoid 
Menactra R © A, C, W, Y Sanofi Pasteur SA, Lyon, France Diphtheria toxoid 
Menveo R © A, C, W, Y GlaxoSmithKline Biologicals SA, Rixensart Belgium Diphtheria cross 
Nimenrix R © A, C, W, Y Pfizer Inc., New York, NY, USA Tetanus toxoid 
Combination conjugate vaccines 
Menitorix R © C + Haemophilus influenzae type b GlaxoSmithKline Biologicals SA, Rixensart Belgium Tetanus toxoid 
Subcapsular meningococcal antigen vaccines 
Bexsero R © B GlaxoSmithKline Biologicals SA, Rixensart Belgium - 
Trumenba R © B Wyeth Pharmaceuticals Inc., Philadelphia, PA, USA ∗ - 
∗a subsidiary of Pfizer Inc. 
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a  ence significant complications, with 9% having major life-long dis-
abling sequelae. 2 , 3 In many areas of the world, the gold-standard
method of active surveillance and laboratory confirmation with
strain characterisation is not possible. Thus, different combinations
of active and passive surveillance with variable diagnostic meth-
ods are used in different countries, making ascertainment of true
IMD burden and comparison across regions difficult. Understand-
ing the local epidemiology, trends over time and impact of vari-
ous immunisation vaccination programmes is important not only
in understanding how such programmes impact disease patterns
but also to identify knowledge gaps and potential for further re-
ductions in disease burden through additional preventive strategies
as new, more effective and higher-valent meningococcal vaccines
become available. 
The responsible pathogen for IMD, Neisseria meningitidis (the
meningococcus), is a Gram-negative diplococcus, an obligate hu-
man pathogen that commonly colonises the upper respiratory
tract. 4 The meningococcal polysaccharide capsule is a major viru-
lence factor and the foundation of the categorisation and nomen-
clature of the bacteria referred to as the serogroup. 4 There are
12 meningococcal serogroups: A,B,C,E,H,I,K,L,X,W,Y and Z. Half of
these (A,B,C,W,X and Y) are responsible for almost all IMD cases
globally, with great variation in serogroup by geographic region.
IMD affects individuals of all ages, but the highest incidence is
in infants and young children as well as older adults, where case
fatality rates (CFR) are high, often due to underlying comorbidi-
ties. 5 Many, but not all countries also have a small peak in IMD
incidence during late adolescence and early adulthood. 6 IMD com-
monly manifests as meningitis or septicaemia, or a combination
of the two; less common presentations include pneumonia, septic
arthritis, pericarditis, supraglottitis or epiglottitis. 7 
Meningococcal vaccines 
Vaccination is the key method of IMD prevention. Vaccines con-
taining the polysaccharide capsule of single or multiple meningo-
coccal serogroups have been available for more than 40 years. 8 
While these remain ineffective in young children, they have been
proven to be immunogenic and safe in older children and adults.
They are, however, unable to induce immunological memory and,
therefore, have a short duration of protection with poor responses
to booster doses. 8 Polysaccharide vaccines are still used, mainly
in lower- and middle-income countries (LMICs), due to their
low cost. 9 Polysaccharide-protein conjugate vaccines, on the other
hand, use a carrier protein to present the meningococcal capsu-
lar polysaccharide to the immune system, in a manner that in-
duces a T-cell mediated response. 4 As a result, these vaccines are
immunogenic from birth, induce immune memory, protect for aonger duration and provide a booster response with subsequent
oses. 10 In addition to providing direct protection in vaccinated
ndividuals, protein-conjugate vaccines also prevent acquisition of
arriage, thus disrupting transmission to others and inducing indi-
ect (herd) protection across the population. 11 The different mono-
alent and multivalent conjugate vaccines currently available are
ummarised in Table 1 . Both polysaccharide and protein-conjugate
accines are available against serogroups A, C, W and Y; since these
accines are composed of the polysaccharide capsule, they do not
rovide cross-protection against other meningococcal serogroups.
olysaccharide-protein conjugate vaccines against MenB, however,
ave been difficult to develop because its polysaccharide contains
omponents that are similar to human foetal neuronal cells and
re, therefore, poorly immunogenic with the potential to induce
utoimmune antibodies. 12 
In the past, MenB vaccines have been successfully developed
gainst specific outbreak strains using their outer membrane vesi-
les (OMV) where the immunodominant antigen is the Porin A
PorA). 13 Such vaccines, however, provide little cross-protection
gainst other MenB strains with diverse PorAs. 14 A novel, multi-
omponent protein-based vaccine (4CMenB; GSK Biologicals) was
icensed in the UK in 2013 and in the US in 2015, with the aim of
roviding broad protection against MenB disease. 4CMenB consists
f three subcapsular recombinant protein antigens which include
adA (Neisserial adhesion A), NHBA (Neisseria heparin binding
ntigen) and fHbp (factor H binding protein) as well as the outer
embrane vesicle of the New Zealand outbreak containing PorA
.4 (NZ OMV). 15 4CMenB protects against most but not all MenB
trains causing invasive disease, with strain coverage ranging from
6% to 91% in different parts of the world. 16 Although the vaccine
as licensed on immunogenicity and safety studies only, there is
ow robust evidence of its effectiveness and impact against IMD
n the real world. 17 , 18 4CMenB is, however, unlikely to provide any
ndirect (herd) protection as it does not reduce meningococcal car-
iage in teenagers. 19 Another MenB vaccine, rLP2086 (Trumenba,
fizer), was licensed in the US in 2014 and in the EU in 2017. This
accine is composed of two fHbp variants (variants 1 and 3 or sub-
amilies A and B) in a lipidated form, which is present in nearly all
nvasive MenB strains, but is currently only licensed from 10 years
f age. 20 Countries and regions that have implemented a MenB
accine are summarised in Table 2 . Although only licensed to pro-
ect against MenB disease, both vaccines have the potential to pro-
ect against any meningococcal serogroup that possesses a vaccine-
elated surface antigen. 21 , 22 For the first time, therefore, we have
ffective vaccines against all the major meningococcal serogroups
ausing IMD worldwide. The MenB and MenACWY vaccines are be-
ng implemented in many countries, targeting different age groups
nd populations, depending on local epidemiology and local neces-
S.R. Parikh, H. Campbell and J.A. Bettinger et al. / Journal of Infection 81 (2020) 483–498 485 
Table 2 
Countries and regions that have implemented the meningococcal B (MenB) vaccine into their national immunisation programmes; currently, all countries are utilising 
4CMenB in their programmes 
Country 
Year 
introduced Routine recommendations Reference 
Andorra 2016 NIP: Infants (2 + 1 at 2moa) Government of Andorra. 2016. Vaccination schedule. 
http://www.salut.ad/images/stories/Salut/pdfs/temes _ salut/Targeto _ Vacunes.pdf 
Ireland 2016 Infants ≥2 months of age 
2 + 1 vaccination schedule (at 2, 4 and 
12 months) 
https://www.hse.ie/eng/health/immunisation/pubinfo/pcischedule/immschedule/ 
Italy 2017 All infants ≥2 months to 2 years of 
age 
3 + 1 vaccination schedule 
http://www.salute.gov.it/imgs/C _ 17 _ pubblicazioni _ 2571 _ allegato.pdf 
San Marino 2017 All infants ≥2 months to 2 years of 
age 
3 + 1 vaccination schedule 
http://www.iss.sm/on- line/home/vaccini- e- vaccinazioni/ 
vaccinazioni-raccomandate.html 
Lithuania 2018 All infants aged ≥2 months 
2 + 1 vaccination schedule (at 3, 5, and 
12–15 months) 
https://e-seimas.lrs.lt/portal/legalAct/lt/TAD/ 
f4a925d0f50f11e79a1bc86190c2f01a?positionInSearchResults= 
0&searchModelUUID=1561434a- b283- 4be2- 87f5- 4f556ad37c32 
UK 2015 Infants ≥2 months of age 
2 + 1 schedule (at 2, 4 and 12 months) 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/ 
attachment _ data/file/741543/Complete _ immunisation _ schedule _ sept2018.pdf 
USA 2015 Healthy adolescents/young adults 
aged 16–23 years 
(preferred age: 16–18 years) 
Category B national recommendation † 
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6441a3.htm , 
https://www.cdc.gov/vaccines/schedules/downloads/child/ 
0- 18yrs- child- combined- schedule.pdf , https://www.cdc.gov/vaccines/schedules/ 
downloads/adult/adult- combined- schedule.pdf 
South Australia 2019 Infants, 1-4 year-olds and 15–20 
years-olds 
https://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+ 
internet/about+us/reviews+and+consultation/meningococcal+b+program+for+ 
south+australia 
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t  ity . In this review, meningococcal experts across different conti-
ents review the ever-changing epidemiology of IMD in their re-
ion, highlighting the successes of past and current meningococcal
mmunisation programmes and providing insight into potential fu-
ure preventive strategies. 
urope 
In Europe, the incidence of IMD has been declining since the
arly 20 0 0s. 23 In 2017, there were 3,221 confirmed IMD cases re-
orted to the European Center for Disease Control and Prevention
ECDC) by 30 EU/EEA countries, with an overall notification rate
f 0.62 cases per 100 000 population. IMD incidence in Europe
anged from 0.45 (Northern and Southern Europe) to 1.33 (UK and
reland) cases per 10 0,0 0 0 population ( Fig. 1 ). There were 282 fa-
al cases reported, with a case fatality of 9.7% ( Table 3 ). IMD inci-
ence was highest in infants aged < 1 year (8.2/10 0,0 0 0) followed
y toddlers aged 1-4 years (2.5/10 0,0 0 0) and with a second peak
n 15–24 year-olds (1.0/10 0,0 0 0). 
MenB currently predominates in Europe, although MenW and
enY predominate in some areas ( Fig. 2 ). 6 The introduction of
enC-containing vaccines in national immunisation programmes
cross Europe has resulted in a significant decline in the pro-
ortion of MenC-disease causing IMD in Europe, without affect-
ng other serogroups. 24-26 Of the 2979 (92%) notifications with
erogroup reported to ECDC, 51% were MenB (n = 1527), followed
y MenW (17%, n = 511) and MenC (16%, n = 485). However, MenY
nd MenW were main serogroups in the Northern EU region com-
ared to MenB followed by MenC in the Central and Southern EU
egion; and MenB and MenW in UK and Ireland ( Fig. 2 ). 
In Europe, the highest IMD incidence was in the Republic of
reland (1.48/10 0,0 0 0), while the United Kingdom had the high-
st number of confirmed cases reported (n = 772) in 2017 ( Table
 ). Overall, IMD incidence in the UK and Ireland was more than
wice the mean in Europe (1.33 vs 0.62/10 0,0 0 0). In the UK, IMD
s a notifiable disease in all four nations (England, Scotland, Walesnd Northern Ireland), each with their own surveillance for IMD. In
ngland, Public Health England conducts IMD surveillance nation-
lly and maintains consistently high case ascertainment through its
ational reference laboratory. 27 Scotland, 28 Wales. 29 and Northern
reland. 30 all have surveillance systems in place and provide regu-
ar updates on IMD epidemiology online. 
In 1999, the UK was the first country to introduce a MenC con-
ugate vaccine to control a national outbreak of invasive MenC
isease due to a hypervirulent strain belonging to clonal com-
lex 11 (MenC:cc11). 31 Many other countries followed suit, result-
ng in large and sustained declines in MenC disease across Eu-
ope. 24-26 Since 2009/10, the UK has been experiencing a national
utbreak of MenW:cc11, which initially originated from South
merica. 32 By 2014/15, MenW was responsible for 24% of all IMD
ases across England, associated with severe disease and fatalities
cross all age groups. 33 This led to the emergency implementa-
ion of a MenACWY conjugate vaccine programme for 13-18 year-
lds in August 2015 to provide direct protection to teenagers and,
ver time, indirect (herd) protection across the population. After
he first year, there were 69% fewer MenW cases than predicted
y trend analysis in MenACWY-eligible adolescents and no cases
n the vaccinated cohorts. 34 Other European countries have re-
orted increases in MenW cases since 2014/15, many of them also
ecommending MenACWY vaccination in different age groups. 35 
p-to-date recommendations for meningococcal vaccination across 
ifferent European countries can be found on the ECDC web-
ite: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease? 
electedDiseaseId=48&SelectedCountryIdByDisease=-1 . 
In the UK, as in most of Europe, MenB disease has been declin-
ng since the early 20 0 0s due to secular trends, 36 reaching its low-
st incidence in 2013/14 (1.1/10 0,0 0 0; 636 cases). 27 In September
015, the UK became the first country to introduce 4CMenB into
ts nationally-funded, infant immunisation programme. 17 Within
0 months of the programme, there was a 50% (95% CI, 29%-64%)
eduction in MenB cases compared to the pre-vaccine period in
he 4CMenB-eligible infants, irrespective of the infants’ vaccination
486 S.R. Parikh, H. Campbell and J.A. Bettinger et al. / Journal of Infection 81 (2020) 483–498 
Fig. 1. Incidence if invasive meningococcal disease (IMD) in Europe during 2017. Reproduced from the ECDC 2017 Annual Report ( https://www.ecdc.europa.eu/sites/default/ 
files/documents/AER _ for _ 2017- invasive- meningococcal- disease.pdf ) 
Fig. 2. Serogroup distribution of invasive meningococcal disease (IMD) cases in Europe during 2017. Reproduced from the ECDC 2017 Annual Report ( https://www.ecdc. 
europa.eu/sites/default/files/documents/AER _ for _ 2017- invasive- meningococcal- disease.pdf ) 
S.R. Parikh, H. Campbell and J.A. Bettinger et al. / Journal of Infection 81 (2020) 483–498 487 
T
a
b
le
 
3
 
N
u
m
b
e
r 
o
f 
ca
se
s 
a
n
d
 
in
ci
d
e
n
ce
 
o
f 
in
v
a
si
v
e
 
m
e
n
in
g
o
co
cc
a
l 
d
is
e
a
se
 
(I
M
D
) 
o
v
e
ra
ll
 
a
n
d
 
b
y
 
m
aj
o
r 
se
ro
g
ro
u
p
s 
a
s 
w
e
ll
 
a
s 
o
v
e
ra
ll
 
IM
D
 
d
e
a
th
s 
a
n
d
 
ca
se
 
fa
ta
li
ty
 
ra
te
s 
(C
F
R
) 
in
 
E
u
ro
p
e
 
R
e
g
io
n
 
IM
D
 
C
a
se
s 
IM
D
 
in
ci
d
e
n
ce
 
IM
D
 
d
e
a
th
s 
C
F
R
 
(%
) 
M
e
n
B
 
ca
se
s 
M
e
n
B
 
in
ci
d
e
n
ce
 
M
e
n
C
 
ca
se
s 
M
e
n
C
 
in
ci
d
e
n
ce
 
M
e
n
Y
 
ca
se
s 
M
e
n
Y
 
in
ci
d
e
n
ce
 
M
e
n
W
 
ca
se
s 
M
e
n
W
 
in
ci
d
e
n
ce
 
E
U
 
(t
o
ta
l)
 
3
2
2
1
 
0
.6
2
 
2
8
2
 
9
.7
 
1
5
2
7
 
0
.3
 
4
8
5
 
0
.0
9
 
3
4
5
 
0
.0
7
 
5
1
1
 
0
.1
 
N
o
rt
h
e
rn
 
E
U
 
3
1
 
0
.4
5
 
5
 
1
0
.2
 
5
 
0
.0
9
 
4
 
0
.0
5
 
1
0
 
0
.1
5
 
9
 
0
.1
3
 
N
o
rw
a
y
 
1
8
 
0
.3
4
 
0
 
0
 
3
 
0
.0
6
 
2
 
0
.0
4
 
8
 
0
.1
5
 
5
 
0
.1
 
S
w
e
d
e
n
 
4
9
 
0
.4
9
 
1
0
 
2
0
.4
 
7
 
0
.0
7
 
7
 
0
.0
7
 
1
4
 
0
.1
4
 
1
7
 
0
.1
7
 
F
in
la
n
d
 
1
6
 
0
.2
9
 
- 
- 
3
 
0
.0
5
 
4
 
0
.0
7
 
9
 
0
.1
6
 
0
 
0
 
D
e
n
m
a
rk
 
3
9
 
0
.6
8
 
- 
- 
1
0
 
0
.1
7
 
1
 
0
.0
2
 
8
 
0
.1
4
 
1
4
 
0
.2
4
 
C
e
n
tr
a
l 
E
u
ro
p
e
 
2
8
0
 
0
.7
9
 
3
3
 
9
.2
 
1
2
6
 
0
.3
8
 
5
0
 
0
.0
9
 
3
9
 
0
.1
2
 
4
7
 
0
.1
7
 
F
ra
n
ce
 
5
4
5
 
0
.8
1
 
6
2
 
1
1
.6
 
2
2
6
 
0
.3
4
 
1
4
9
 
0
.2
2
 
7
8
 
0
.1
2
 
7
4
 
0
.1
1
 
B
e
lg
iu
m
 
9
6
 
0
.8
5
 
- 
- 
6
0
 
0
.5
3
 
6
 
0
.0
5
 
1
9
 
0
.1
7
 
9
 
0
.0
8
 
N
e
th
e
rl
a
n
d
s 
1
9
8
 
1
.1
6
 
1
6
 
8
.3
 
8
1
 
0
.4
7
 
9
 
0
.0
5
 
2
7
 
0
.1
6
 
8
0
 
0
.4
7
 
G
e
rm
a
n
y
 
2
8
1
 
0
.3
4
 
2
2
 
7
.9
 
1
3
9
 
0
.1
7
 
3
8
 
0
.0
5
 
3
3
 
0
.0
4
 
2
4
 
0
.0
3
 
S
o
u
th
e
rn
 
E
u
ro
p
e
 
1
3
9
 
0
.4
5
 
1
2
 
8
.7
 
6
8
 
0
.2
4
 
2
2
 
0
.0
5
 
1
5
 
0
.0
4
 
1
1
 
0
.1
1
 
P
o
rt
u
g
a
l 
4
9
 
0
.4
8
 
3
 
6
.1
 
3
2
 
0
.3
1
 
2
 
0
.0
2
 
4
 
0
.0
4
 
1
 
0
.0
1
 
S
p
a
in
 
2
6
8
 
0
.5
8
 
2
4
 
9
.1
 
1
3
9
 
0
.3
 
2
6
 
0
.0
6
 
1
8
 
0
.0
4
 
2
7
 
0
.0
6
 
It
a
ly
 
1
9
7
 
0
.3
3
 
2
0
 
1
2
.5
 
7
4
 
0
.1
2
 
5
7
 
0
.0
9
 
3
4
 
0
.0
6
 
1
2
 
0
.0
2
 
G
re
e
ce
 
4
2
 
0
.3
9
 
3
 
7
.1
 
2
6
 
0
.2
4
 
1
 
0
.0
1
 
2
 
0
.0
2
 
2
 
0
.0
2
 
U
K
 
+ 
Ir
e
la
n
d
 
4
2
1
 
1
.3
3
 
2
5
 
9
.1
 
2
1
9
 
0
.6
1
 
4
2
 
0
.3
4
 
4
2
 
0
.0
7
 
1
1
5
 
0
.2
9
 
U
K
 
7
7
2
 
1
.1
7
 
4
3
 
5
.6
 
4
1
0
 
0
.6
2
 
5
5
 
0
.0
8
 
8
2
 
0
.1
2
 
2
1
7
 
0
.3
3
 
Ir
e
la
n
d
 
7
1
 
1
.4
8
 
7
 
1
2
.5
 
2
8
 
0
.5
9
 
2
8
 
0
.5
9
 
1
 
0
.0
2
 
1
2
 
0
.2
5
 
s  
p  
8  
a  
d
 
c  
w  
s  
s  
fi  
d  
n
A  
r  
c  
a  
g  
r
 
1  
c  
t  
i  
M  
(  
p  
a  
p  
(  
M  
t  
o  
v  
d  
i  
c  
w  
5  
i  
m  
0
 
E  
o  
w  
t  
a  
y  
a  
f  
8  
c  
n
2  
T  
v  
f  
f
 
fi  
t  
t  
c  
1  
t  tatus or predicted MenB strain coverage. A reduced 2-dose infant
riming schedule at 8 and 16 weeks of age was estimated to be
2.9% (95% CI, 24.1-95.2%) effective against all MenB cases, equiv-
lent to a vaccine effectiveness of 94.2% against the highest pre-
icted MenB strain coverage of 88%. 17 
After the first three million doses administered to 1.3 million
hildren aged 2-18 months in the UK, no major safety concerns
ere identified. 18 In particular, there was no evidence of increased
eizures within seven days of immunisation, Kawasaki disease or
udden infant death. Additionally, almost all infants receiving their
rst dose of 4CMenB at 8 weeks of age returned for their second
ose at 16 weeks of age, indicating that 4CMenB introduction had
ot reduced compliance with doses of other routine vaccinations. 18 
fter three years of the programme, 4CMenB has been shown to
educe 62% (446 cases expected, 169 cases confirmed) of MenB
ases in vaccine-eligible infants in England and protects children
t least until their third birthday. 37 IMD trends in other UK regions
enerally reflect those observed in England, but are reported sepa-
ately by the individual regions. 
In the Republic of Ireland , IMD incidence increased from
996/97 and peaking at 11.6/10 0,0 0 0 in 1999/20 0 0, 38 before de-
lining to 1.9/10 0,0 0 0 in 2018. 39 Similar to the UK, the introduc-
ion of the MenC conjugate vaccine in 20 0 0 led to large declines
n MenC disease across the population. 38 From 2014, however,
enC disease increased from six cases (0.1/10 0,0 0 0) to 30 cases
0.1/10 0,0 0 0) in 2017 before declining to 20 cases (0.4/10 0,0 0 0
opulation) in 2018, likely because of the introduction of the
dolescent MenC conjugate vaccine booster in 2014. 39 The Re-
ublic of Ireland also had an increase in MenW cases from one
 < 0.1/10 0,0 0 0) case in 2014 to 12 (0.3/10 0,0 0 0) in 2018, as well as
enY cases from three (0.1/10 0,0 0 0) to eight (0.2/10 0,0 0 0 popula-
ion) cases over the same period. This led to the implementation
f the MenACWY conjugate vaccine for adolescents and new uni-
ersity entrants from September 2019. 39 MenB disease has been
eclining in the Republic of Ireland from 292 cases (8.1/10 0,0 0 0)
n 1999 to 46 cases (1.0/10 0,0 0 0) in 2018. 39 Like the UK, large de-
lines were particularly observed among children aged < 5 years,
ith MenB disease incidence more than halving from 2014 to
.7/10 0,0 0 0 (19 cases) in 2018. However, the Republic of Ireland
s one of the few countries that also implemented a national im-
unisation programme offering 4CMenB to all infants born since
1 October 2016. 40 
Central Europe had the second highest IMD incidence in the
U in 2017, with a stable rate since 2006 ( Table 2 ). IMD epidemiol-
gy in the Netherlands has closely followed that of the UK, starting
ith the MenC outbreak in the 1990s that led to the implementa-
ion of a MenC conjugate vaccine programme for Dutch children
ged 14 months in 2002, alongside a catch-up campaign for 1–18
ear-olds. 41 More recently, the Netherlands has been experiencing
 national outbreak of MenW:cc11 disease, with cases increasing
rom an average of 4 (0.02 cases per 10 0,0 0 0) during 2010-14 to
0 cases in 2017 (0.5/10 0,0 0 0) in 2017, representing 40% of all IMD
ases. 42 Incidence was highest in children < 5 years (0.92/10 0,0 0 0;
 = 8), especially < 2 year-olds (2.0/10 0,0 0 0; n = 7), followed by 15–
4 year-olds (0.81/10 0,0 0 0; n = 17) and adults from 45 years of age.
his increase led to the replacement of the toddler MenC conjugate
accine dose at 14 months with the MenACWY conjugate vaccine
rom May 2018 and offering the latter vaccine to 13-14 year-olds
rom October 2018. 
In 2017, France reported the second highest number of con-
rmed IMD cases in Europe (n = 545) but IMD incidence was lower
han in the Netherlands. IMD incidence in France has been rela-
ively stable over the past decade ( Fig. 3 ). The MenC conjugate vac-
ine was introduced in 2010 but the decline in IMD incidence from
.23/10 0,0 0 0 in 20 06 to 0.78/10 0,0 0 0 in 2016 was mainly related
o the secular decline in MenB IMD. 43 MenC disease incidence de-
488 S.R. Parikh, H. Campbell and J.A. Bettinger et al. / Journal of Infection 81 (2020) 483–498 
Fig. 3. Notification rates for invasive meningococcal disease (IMD) per 10 0,0 0 0 by country in (A) the UK and Ireland, (B) Southern Europe, (C) Central Europe and (D) 
Southern Europe. Reproduced from the ECDC 2017 Annual Report ( https://www.ecdc.europa.eu/sites/default/files/documents/AER _ for _ 2017- invasive- meningococcal- disease. 
pdf ) 
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o  reased from 0.29/10 0,0 0 0 in 20 06 to 0.13/10 0,0 0 0 in 2010 but in-
reased thereafter in age groups not targeted by the vaccination
rogramme; this trend may at least in part be explained by poor
accine uptake ( < 25%) among 15-19 year-olds in 2015. Since 2016,
n increase in MenW:cc11 IMD was also reported in France, affect-
ng mainly adults, and associated with a high CFR of 28%. 44 
Germany had the lowest IMD incidence among central EU
ountries in 2017, with declining rates from 0.95/10 0,0 0 0 in 2001
o 0.35/10 0,0 0 0 in 2017. During 2013-16, IMD incidence was high-
st in infants (4.6/10 0,0 0 0) followed by toddlers (1.8/10 0,0 0 0)
nd adolescents (0.73/10 0,0 0 0). 4 MenB was the most prevalent
erogroup (0.27/10 0,0 0 0), accounting for 58% of IMD cases dur-
ng 2013-16; CFR due to MenB (9.4%) was almost as high as
or the second most common serogroup MenC (13.6%; incidence,
.07/10 0,0 0 0 persons). 45 
In Northern Europe , Denmark had the highest IMD incidence
n 2017, followed closely by Sweden since 2012 ( Fig. 2 ). Notifica-
ion rates in both Northern and Southern Europe (0.45/10 0,0 0 0)
ave been lower than in the other European regions. In Southern
urope , Spain had the highest incidence in 2017 (0.58/10 0,0 0 0).
MD incidence reached its lowest in 15 years during 2013/14, fol-
owing MenC conjugate vaccine introduction in 20 0 0 and sec-
lar declines in MenB disease. 6 Since then, however, IMD in-
idence increased because of both MenW and MenY disease. 6 
uring 2016/2017, 321 IMD cases were notified and 270 (84.1%)
ere confirmed; including 139 (51.5%) MenB (0.30/10 0,0 0 0), 31
enC (0.07/10 0,0 0 0), 22 MenW (8.2%), 17 MenY (6.3%) and 10
ther serogroups. 6 Non-typable strains were isolated in 14 and the
erogroup was not identified in 37 confirmed cases. 6 There were
1 clinically-diagnosed cases (0.11/10 0,0 0 0), representing 15.9% of
he total notified cases, lower than in previous seasons ( ∼22%). 6 
enB cases have been declining for 15 years; the moderate up-
ake of MenB vaccine in the private market (reaching 40-50% per
irth cohort) may also be contributing to this decline. 4,6 Between
999/20 0 0 and 2016/2017, the average annual decline was -9.4%
95% CI, -11.3 to -7.6) for MenB and -16.4% (95% CI, -18.9 to -13.9)
or MenC, both statistically significant. 6 
In Eastern Europe , IMD surveillance is limited in many coun-
ries or restricted to acute bacterial meningitis. 46 The overall trend,
owever, has been a declining IMD incidence over recent decades
ith current rates below 1/10 0,0 0 0 population annually, even in
ountries with more robust national surveillance in place and a
FR ranging between 3% and 30%. MenB accounts for 60-90% of
onfirmed IMD cases followed by MenC (30%) and less commonly
enA which has been reported in Romania, Republic of Belarus,
ussia, Azerbaijan and Turkey. 46 Occasional cases due to MenW,
enY and MenX are also emerging in some countries. Both con-
ugate and polysaccharide vaccines are available in Eastern Eu-
ope and but not recommended in national immunisation pro-
rammes in the majority of countries, except for high-risk groups.
n many countries, meningococcal vaccination is recommended but
ot mandatory or reimbursed. 46 
Across Europe, IMD incidence is currently very low and
idespread immunisation may, therefore, not be justified. The re-
ent emergence of MenW:cc11, however, has led many countries to
mplement – or at least recommend – either replacing the MenC
onjugate vaccine or initiating a new programme with the Men-
CWY conjugate vaccine. Offering the vaccine to young children
rotects them directly against the four meningococcal serogroups
hilst offering the vaccine to adolescents has the additional ben-
fit of providing indirect (herd) protection over time if sufficient
accine uptake can be achieved in this age group. Although the
ncidence of MenB disease is currently at its lowest in decades,
ven in infants, countries that implement the newly licensed
enB vaccines will achieve further declines in those who are
accinated. g  orth America 
nited States 
In the United States (US), IMD epidemiology has changed dra-
atically over the past few decades, with the current incidence at
istorically low levels. For many years after World War II, annual
MD incidence fluctuated between 0.5-1.5/10 0,0 0 0. Since the mid-
le of the 1990s, however, IMD incidence has declined > 90% to
.13/10 0,0 0 0 in 2017, with only 310 cases and 50 deaths. 47 Like
any other countries, infants have the highest incidence, with a
maller peak during adolescence and young adulthood and an in-
rease among the elderly. 48 Serogroup distribution for 599 isolates
uring 2006-2015 was: MenB, 38%; MenC, 24%; MenW, 7%; and
enY, 30%. 47 
IMD cases in the US are primarily sporadic, but small out-
reaks are relatively common. Before routine MenACWY vaccina-
ion, MenC caused most outbreaks. 49 but, currently, MenB out-
reaks are more common, mainly among college and university
tudents. 50 During 2008-2017, there were 11 MenB outbreaks, re-
ulting in 53 cases and 3 deaths, 51 , 52 as well as MenC out-
reaks among men who have sex with men. 53 IMD outbreaks can
e extremely disruptive because they often require large, labour-
ntensive and expensive immunisation campaigns. 53-55 
In 2005, the MenACWY conjugate vaccine was recommended
or adolescents, preferably at 11-12 years of age but, because of
apidly waning effectiveness of the MenACWY vaccine conjugated
o diphtheria toxoid (MenACWY-DT; Menactra), 56 a booster dose is
ow recommended at 16 years of age. The vaccine is also recom-
ended for high-risk groups. The MenACWY programme was as-
ociated with a decline in MenC and MenY disease among adoles-
ents and young adults. 48 The decline, however, began in the mid-
990s and the slope of the decline has not been greatly altered by
he vaccines. 51 , 57 In addition to the MenACWY conjugate vaccine,
oth MenB vaccines can be used for 10-25 year-olds. 51 , 57 , 58 and is
ecommended for high-risk individuals as well as 16-23 year-olds
ho are not at increased risk based on “individual clinical decision
aking”. 58 This type of recommendation is problematic because
f major knowledge gaps among physicians about both MenB dis-
ase and vaccines. 59 MenB cases also began to decrease well be-
ore the recent availability of MenB vaccines. The low IMD inci-
ence has made it difficult for policymakers to justify routine vac-
ine use in some age groups because of the remarkably low disease
urden. 
anada 
Historically, IMD incidence in Canada was highest during win-
er with cyclical peaks of epidemic disease occurring every 5-10
ears and sporadic outbreaks arising more frequently. From 1924
the earliest year data were collected) to 1984, the average annual
ncidence was 1.6/10 0,0 0 0 with a high of 3.8/10 0,0 0 0 in the 1940s
riven by MenA to a low of 0.59/10 0,0 0 0 in the 1960s. 60 From
985-20 0 0, annual IMD incidence remained < 2.0/10 0,0 0 0. By the
970s, MenA disease had disappeared, to be replaced with endemic
enC and MenB disease. In the mid-1980s, the MenC:2a serotype
merged in Canada, 61 , 62 peaking in 1992 and again in 20 0 0-20 01,
ith high attack rates and fatalities in adolescents and young
dults. 63 In response, reactive vaccination strategies were imple-
ented in several provinces using polysaccharide vaccine in the
990s followed by the MenC conjugate vaccine when available in
001. 64 As in other developed countries, IMD incidence in Canada
xhibited a bimodal peak with the highest incidence in infants, fol-
owed by 1-4 year-olds and a second smaller peak in 15-24 year-
lds. 65 Consequently, the first universal infant immunisation pro-
rams started in 2001 with the MenC conjugate vaccine in high en-
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Table 4 
Canadian Provincial and Territorial Meningococcal C and Quadrivalent Immunization Programme 
Province/Territory Infants MenC Year Started Children/Adolescents Year Started 
British Columbia 1 2, 12 months 2003 14-16 years 2003 MenC, 2016 ACWY 
Alberta 2 4, 12 months 2002 14-16 years 2002 MenC, 2011 ACWY 
Saskatchewan 12 months 2004 14-16 years 2004 MenC, 2011 ACWY 
Manitoba 12 months 2005 10-11 years 2005 MenC, 2019 ACWY 
Ontario 12 months 2005 12-14 years 2005 MenC, 2009 ACWY 
Quebec 3 18 months 2001 14-16 years 2013 MenC 
New Brunswick 12 months 2004 14-16 years 2004 MenC, 2007 ACWY 
PEI 12 months 2005 14-16 years 2005 MenC, 2006 ACWY 
Nova Scotia 12 months 2005 12-14 years 2005 MenC, 2015 ACWY 
Newfoundland 12 months 2005 10-11 years 2005 MenC, 2009 ACWY 
NWT 4 2, 12 months 2004 17-18 years 2004 MenC, 2007 ACWY 
Nunavut 12 months 2007 14-16 years 2007 MenC, 2017 ACWY 
Yukon 5 2, 12 months 2005 10-11 years 2005 MenC, 2018 ACWY 
MenC = monovalent conjugate serogroup C vaccine 
ACYW = Quadrivalent serogroups ACYW 135 conjugate vaccine 
The following vaccines are authorized for use in Canada and all have been used in provincial and territorial 
programs: Meningitec (Pfizer), Menjugate (Novartis), NeisVac-C (Baxter), Menactra (Sanofi Pasteur), Menveo 
(Novartis). 
1 BC switched from a 1-dose program at 12 months to a 2-dose program at 2 and 12 months in 2005. 
Catch up program with MenC was offered for adolescents 14-18 years of age from 20 04-20 07. 
2 Alberta switched from a 3-dose infant program at 2, 4 and 6 months to 2, 4 and 12 months in 2007 and 
to a 2-dose infant program at 4 and 12 months in January 2015. 
3 Quebec mass immunization of 2 month to 20 year olds in 2001 with MenC. Infant program switched 
from 12 months to 18 months Jan. 1, 2019. 
4 NWT switched from a 2-dose program at 2 and 4 months to a 2-dose program at 2 and 12 months in 
2007. ACYW is provided to post-secondary students attending school outside of NWT. 
5 Yukon switched from a 2-dose program at 2 and 6 months to a 2-dose program at 2 and 12 months in 
2007. 
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vdemicity provinces and was in place nationally by 2005. The Men-
ACWY programme for adolescents began in 2006 and is now used
in all but one province (Quebec) ( Table 4 ). Currently, MenC is ex-
tremely rare across the country (incidence 0.05/10 0,0 0 0), with only
sporadic cases in older, unvaccinated adults. 66-69 The effect of the
MenACWY programmes have been more difficult to measure. 67 , 70 
because of very slow implementation across Canada and low dis-
ease incidence at baseline ( < 0.10/10 0,0 0 0 MenY, < 0.05/10 0,0 0 0
MenW). 71 
In Canada, IMD cases due to the South American MenW:cc11
strain emerged in 2014. 72 and, by 2016, was circulating in five
provinces (British Columbia, Alberta, Manitoba, Ontario and Que-
bec), accounting for 19% of all culture-confirmed IMD. 73 , 74 The
strain was also responsible for a 2017 outbreak among adolescents
in British Columbia that resulted in a mass vaccination programme
in the outbreak jurisdiction. 
Quebec presents different IMD epidemiology from the rest of
Canada. In 20 0 0-20 01, Quebec was the only province to implement
mass MenC vaccination for individuals aged 2 months to 20 years,
which led to a decline in MenC cases. Thereafter, MenB was re-
sponsible for > 80% of cases, with 55% of cases caused by the ST-
269 clonal complex, which emerged in 2003 among adolescents
and spread across all age-groups. 69 In response, Quebec imple-
mented a targeted mass immunisation programme in the jurisdic-
tions with the highest incidence with 4CMenB in 2014. 75 and the
incidence declined from 11.4/10 0,0 0 0 in 20 06-2014 to 0.4/10 0,0 0 0
in 2014-2018 (p < 0.0 0 01). 76 Elsewhere in Canada, MenB vaccine
(4CMenB) has only been used reactively to combat sporadic out-
breaks, 77 although this serogroup continues to account for most
cases in Canada but with low incidence ( ∼0.25/10 0,0 0 0 nation-
ally). 78 Since the initiation of meningococcal vaccination pro-
grammes, Canada has experienced historically low IMD incidence
overall ( < 1.0/10 0,0 0 0), virtual elimination of MenC disease and
very low MenW and MenY incidence, particularly in provinces
with long-standing MenACWY programmes. 70 , 71 entral and South America 
The overall incidence of IMD in Central and South America
aries widely by geographic region, serogroup prevalence and time,
ith a decreasing trend in disease incidence observed in recent
ears. The highest age-specific incidence was consistently observed
n infants less aged < 1 year and, in contrast to Europe, North
merica and Australia, there is no apparent second peak of inci-
ence in adolescents in the region. 79 Most IMD cases are sporadic,
ith outbreaks occurring at irregular intervals. Although IMD re-
orting is mandatory in the region, surveillance and reporting sys-
ems, as well as the quality of published data for IMD are not uni-
orm across the countries, with limited robust data available and
xceedingly low rates of meningococcal disease reported by some
ountries. Additionally, limited access to hospital care, lack of ad-
quate laboratory-based microbiologic infrastructure incorporating
olecular methods in routine testing and restrictive case defini-
ions of IMD in some countries may contribute to underestimate
he true burden of disease in the region. Brazil, Chile and Argentina
re the countries with the highest IMD burden in Central and
outh America, probably reflecting more robust surveillance and a
ell-established laboratory infrastructure for IMD. 79 Serogroups B,
 and W are responsible for most IMD cases reported in the re-
ion, with rare reports of MenY, while serogroup A has not been
irculating for many years. 80 Much like the epidemiology of IMD,
outine meningococcal vaccination programmes also vary by coun-
ry in this region ( Table 5 ). 
In Brazil , the health authorities incorporated the MenC conju-
ate vaccine in the National Immunization Program in late 2010.
his was motivated by a significant rise in the number and pro-
ortion of cases due to MenC, associated with the ST-103 complex,
ith several outbreaks affecting different regions across the coun-
ry and a CFR of 20%, The program resulted in an immediate reduc-
ion in MenC cases among < 2 year-olds, the age group targeted for
accination. 81 , 82 
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Table 5 
Latin American countries with routine meningococcal vaccination programmes. 
Country Infants and children / Vaccine Year started Adolescents / Vaccine Year started 
Cuba MenB OMV 
3 and 5 months 
1991 - 
Brazil MenC conjugate 
3, 5 and 12-15 months 
2010 MenC conjugate 
11-14 years 
2017 
Chile MenACWY conjugate 
- 9 months – 5 years 
- 12 months 
2012 
2014 
- 
Argentina MenACWY conjugate 
3, 5, 15 months 
2017 MenACWY conjugate 
11 years 
2017 
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t  Since 2017 adolescents aged 11-14 years were also included in
he MenC immunisation programme and, from 2020, the Men-
CWY conjugate vaccine will replace the MenC vaccine for ado-
escents. In 2018, according to the Notifiable Diseases Information
ystem (SINAN), 1,131 cases of IMD were reported, with an inci-
ence of 0.54 cases/10 0,0 0 0 population, the lowest incidence re-
orted in the last 30 years. MenC remains the leading cause of
MD, responsible for 53% of the identified cases in 2018, followed
y MenB (27%), MenW (16%) and MenY (3%). 83 
In Chile , after a long period of MenB predominance and sta-
le incidence rates, IMD incidence doubled in 2012 (0.8/10 0,0 0 0)
omparing to 2011, associated with the emergence of a hyperviru-
ent genetic lineage MenW: P1.5, 2:ST-11, responsible for > 80% of
he identified cases. In addition, unusual clinical presentations in-
luding gastrointestinal symptoms, increased morbidity, and CFR as
igh as 28% have been reported for the South American MenWcc11
ublineage. 84 In 2012, Chile implemented a reactive immunization
ampaign with MenACWY conjugate vaccines, initially targeting
hildren aged 9 months to 5 years and, after 2014, as a one-dose
chedule at 12 months of age. As expected, the MenACWY pro-
ramme resulted in significant reductions in cases among vaccine-
ligible children (1-5 year-olds) but cases in other age groups con-
inued to increase. Consequently, MenW disease incidence in 2016
0.34/10 0,0 0 0) was similar to 2012 (0.37/10 0,0 0 0). 
In Argentina, approximately 120-300 cases were reported dur-
ng 2012-2016, with incidence declining from 0.75/10 0,0 0 0 in 2012
o 0.28/10 0,0 0 0 in 2016. IMD incidence was highest in infants
nd overall CFR was 10%. In 2016, MenB was the predominant
erogroup, responsible for 54.3% of identified cases, followed by
enW (33.3%), MenC and MenY (6.2% each). In 2017, the Men-
CWY conjugate vaccine was introduced in the national immuni-
ation programme for infants at 3, 5 and 15 months, with a dose
or adolescents at 11 years of age. 85 
In Colombia , the median IMD incidence during 2013-2016 was
.16/10 0,0 0 0, with the highest incidence in infants and overall CFR
f 13-21%. MenC became the predominant serogroup causing IMD
ince 2015, with several outbreaks reported in the country. 86 
In Mexico , IMD is considered to be rare, with incidence as
ow as 0.01/10 0,0 0 0 reported during 2014-2017 [9]. However,
ecent active-surveillance-based studies across different regions
ound significantly higher IMD rates, associated predominantly
ith MenC disease. 87 Central America, Caribbean and Andean
ountries also report very low incidence rates of disease. Since
991, Cuba has been routinely using a locally produced MenB OMV
accine as well as a MenC polysaccharide vaccine in its childhood
mmunization schedule, which are given at 3 and 5 months of age.
onsequently, IMD incidence has remained very low and nearly all
ases reported in recent years are due to MenB. 88 
Overall, in Central and South America, the predominance of
enC and, more recently, MenW has led to widespread implemen-
ation of the MenACWY immunisation programme, mainly in coun-ries with adequate surveillance in place. Experience from Chile
onfirms the high effectiveness of the MenACWY vaccine in chil-
ren but highlights the importance of vaccinating teenagers – the
ge group with the highest meningococcal carriage – to achieve
isease control across the population by preventing carriage and
nterrupting onward transmission. The success of the Cuban im-
unisation programme, including the childhood meningococcal B
MV and the adolescent MenACWY programmes, is commendable.
here is a desperate need to improve IMD surveillance across the
egions as well as standardising diagnostics and case definitions so
hat vaccine recommendations can reflect local epidemiology. 
frica and the Middle East 
eningitis Belt 
Historically, the meningitis belt in Northern Africa has had the
ighest IMD incidence in the world. This region spans across 26
ountries, from Senegal in the West to Ethiopia in the East, with
 population of nearly 300 million. 89 Periodic epidemics occur and
he timing of the epidemic season varies from year to year and
ountry to country. The epidemics typically occur during the dry
eason which can be earlier in the East and later in the West.
arge-scale epidemics occur every 5 to 12 years when IMD attack
ates can reach 10 0-80 0/10 0,0 0 0, with individual countries report-
ng rates up to 1,0 0 0/10 0,0 0 0 population (i.e. 1% of the popula-
ion). The case fatality rate ranges from 6.6 to 10.0% and perma-
ent sequelae including hearing loss and motor impairment affect-
ng over 30% and 12% of survivors, respectively. 89 
Historically, the outbreaks have been due to MenA, which was
esponsible for nearly all IMD cases in sub-Saharan Africa. 90 A re-
ent study showed that even during epidemics, the responsible
enA strains may be heterogeneous with several closely-related
ut genetically distinct co-circulating clones, highlighting the dy-
amic nature of the meningococcal genome. 91 A MenA conjugate
accine, MenAfriVac, (Serum Institute of India Pvt, Pune, India) was
eveloped as part of the Meningitis Vaccine Project (MVP), which
as created as a partnership between WHO, Bill & Melinda Gates
oundation and the Program for Appropriate Technology in Health
PATH) in 2001. 92 The MenAfriVac programme was implemented
n 2010 and by 2016, more than 235 million persons aged 1–29
ears in 16 countries had received a single dose of MenAfriVac. 89 
his led to a 57% decline in suspected meningitis cases with cor-
esponding 59% reduction in epidemics and 99% decline in con-
rmed MenA cases during 2010–2015, such that, during 2016–2017,
enA was responsible for only 0.8% of 2,897 confirmed IMD cases
n the region. 89 Consequently, IMD epidemiology has shifted and
ost disease is now caused by MenC, MenW and MenX. 
In 2013, a novel MenC strain emerged in Nigeria and by 2017
ad spread to Niger and across Northern Nigeria, causing more
han 30 0 0 0 cases and almost 2500 deaths in 2017. This new hy-
492 S.R. Parikh, H. Campbell and J.A. Bettinger et al. / Journal of Infection 81 (2020) 483–498 
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i  perinvasive MenC ST-10217 clone (unassigned clonal complex) was
genetically distant from previous MenC strains and only found in
the African meningitis belt. 93 In 2017, a meningococcal outbreak
associated with high attack and case fatality rates at a funeral in
Liberia was identified to be due to MenC which was similar to
ST-10217. 53 MenW can occasionally cause epidemics in the menin-
gitis belt. Notably, MenW caused large-scale outbreaks affecting
thousands in Ghana and Togo during 2016. 94 MenW is responsible
for around a third of meningococcal meningitis confirmed in the
meningitis belt. 89 MenX is a rare cause of IMD but has occasion-
ally caused outbreaks and small epidemics in the meningitis belt.
An increase in MenX has been reported recently, with the propor-
tion of cases increasing from 2.7% of 4150 confirmed cases dur-
ing 2013–2016 to 22.0% of 1410 cases in 2017, mainly from Niger,
Burkina Faso and Togo. 94 There are currently no licensed vaccines
against MenX, although clinical trials are-ongoing. 95 
Outside the Meningitis Belt 
Outside the meningitis belt, data are scarce apart from South
Africa, where established IMD surveillance is in place and vac-
cine use is negligible. 96 IMD incidence was 0.97/10 0,0 0 0 in 20 03,
peaked to 1.4/10 0,0 0 in 20 06 and declined to 0.23/10 0,0 0 0 in 2016,
most likely due to secular trends. 96 Of 3,917 cases with confirmed
serogroups, MenW was responsible for 49.5%, MenB 23.3%, MenY
12.3%, MenC 9.4% and MenA 4.7%. Of those tested, 37% were HIV-
positive and HIV-infected persons had a 2.5-fold higher risk of IMD
and patients; additionally, HIV co-infection was twice as common
in patients with MenW and MenY disease. The in-hospital CFR was
17%. 
In Malawi, N. meningitidis was responsible for < 5% of bacterial
meningitis in children. 97 A prospective study in rural Mozambique
estimated an IMD incidence of 11.6/10 0,0 0 0 in children under 15
years during 1998-2008, with MenW:cc11 being responsible for
81% of tested isolates. 98 A more recent hospital-based study from
Mozambique reported MenA to be responsible for 50% of meningo-
coccal meningitis cases during 2014, followed by MenW/Y (19%),
MenC (8.5%), MenX (7.5%) and MenB (0.9%). 99 
Above the meningitis belt, there has been a shift from MenA
to MenB disease in Northern Africa. Although no formal surveil-
lance is in place in Tunisia, data from one hospital show that 85%
of cases occur in children aged < 5 years and MenB is responsi-
ble for 80% of cases. 100 In Morocco, IMD incidence is estimated
to be 2.0-3.6/10 0,0 0 0 and 95% of cases during 2011-15 were due
to MenB, followed by MenC (2%), MenY (2%) and MenW (2%). 100 
IMD incidence in Algeria was estimated to be 0.09/10 0,0 0 0 over-
all and 0.48/10 0,0 0 0 in children aged < 5 years. Both MenB and
MenW also cause IMD, but MenY appears to be rare. 100 In Egypt, N.
meningitidis was identified in 16% of confirmed cases, with MenB
responsible for 51% of 135 cases, followed by MenA (35%) and
MenW (4%). 101 
In summary, MenA has been nearly eliminated in the African
meningitis belt following a massive global effort that led to the
vaccination of millions of children and young adults across many
countries. The emergence of other serogroups in the region,
however, highlights the importance for on-going surveillance and
emphasises the need for affordable multi-serogroup conjugate
vaccines for the region. Outside the meningitis belt, the most
robust data come from South Africa and the declining incidence
is reassuring but on-going surveillance is vital to support lo-
cal and national vaccine recommendations. Elsewhere, data are
scarce. Establishing routine surveillance to monitor both inci-
dence and trends over time for the major infectious diseases,
especially vaccine-preventable diseases including IMD, need to be
prioritised. sia 
hina 
Before 1980s, meningococcal disease had been serious public
ealth problem in China. The highest incidence was 403/10 0,0 0 0
ith a CFR of 5.3% in 1967. 102 Most of the cases were caused
y MenA, with a small proportion of cases due to MenB, which
ere generally sporadic and had not caused significant public
ealth concern. In the early 1980s, therefore, polysaccharide vac-
ines against MenA were incorporated into the routine immunisa-
ion programme which led to significant declines in MenA disease.
rom 1990s, the incidence decreased to and remained at lower
han 1/10 0,0 0 0. The most prevalent serogroup had been MenA un-
il 2003 when MenC belonging to a novel clonal complex (ST-
821) emerged and caused several outbreaks and many sporadic
ases. 103 To combat this serogroup replacement from group A to
, several polysaccharide vaccines against MenC or MenAC were
ntroduced into the Expanded Programme for Immunization (EPI)
n China in 2008. IMD is one of 39 statutorily notifiable diseases
n China, all cases, including suspected cases, must be reported
o the Chinese Center for Disease Control and Prevention via the
ational Notifiable Disease Reporting System (NNDRS). According
o the data from the NNDRS, meningococcal disease incidence
as 0.047/10 0,0 0 0 during 20 06-2014. 104 and 0.0 079/10 0,0 0 0 dur-
ng 2015-2017, 105 although these are likely to be underestimated,
ince a recent meta-analysis of 11 albeit heterogeneous regional
bservational studies and representing only a small proportion
f the Chinese population estimated an average incidence rate of
.84/10 0,0 0 0 (95%CI, 0.91–3.37) and CFR of 33% (95%CI, 0.12-0.86)
uring 20 0 0-2010. 106 Of the notified cases, however, CFR during
006-14 and 2015-17 were 9.6% and 14.2%, respectively. Between
hese periods, the serogroups responsible for IMD have changed
ubstantially and become more complicated. The percentage of
enA cases continued to decline and that of MenC cases de-
reased after initially increasing. MenB cases have increased sig-
ificantly and account for more than half of the serogroup-defined
ases. Invasive cases caused by MenW had not been observed un-
il 2006 and then caused sporadic cases and outbreaks in several
rovinces, 107 , 108 accounting for an increasing proportion of IMD
ationally (4.2% during 2006-2014 to 6.1% during 2015-2017). 104 , 105 
enX and MenY invasive cases were observed but not associated
ith any geographical spread or increase in cases. The highest CFR
as due to MenW (32.4%), followed by MenB (15.6%). 104 , 105 
In the decades since 1956 when the first strain was isolated
n China, the molecular characteristics of meningococci has also
hanged dramatically. The earliest MenA isolated in the 1950s be-
onged to ST-5 (ST-5 clonal complex, cc5). 109 Since 1960s, ST-3
cc1) emerged and gradually became the main clonal lineage. After
980, ST-7 (cc5) gradually took over ST-3 and has been the pre-
ominating clonal lineage. Comparatively, MenC cases are mainly
ue to a single clonal lineage, cc4821, since it was identified in
003. 110 Currently, cc4821 has been identified in 30 provinces and
ccount for > 95% of the invasive MenC cases nationally. 
Before 2004, MenB had no dominant lineage and generally
aused sporadic infections. The hyper-invasive clonal complexes
revalent in many other countries, such as cc32 and cc41/44, 111 
ere rarely isolated in China. Since 2005, MenB disease and car-
iage have both increased. Among the MenB isolates, cc4821 was
he most common clonal lineage. Analysis based on whole genome
equencing showed that there could be multiple recombination
vents between cc4821 MenB and MenC. 112 In 2006, both cc4821
nd cc11 MenW were isolated from invasive cases. 113 In the fol-
owing years, cc11 exceeded cc4821 in terms of both transmis-
ion and the number of isolates, with cc11 accounting for most
nvasive MenW cases. At present, MenW:cc11 is circulating in at
S.R. Parikh, H. Campbell and J.A. Bettinger et al. / Journal of Infection 81 (2020) 483–498 493 
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n  east 12 provinces dispersed throughout China. Whole genome
equence-based analysing revealed that the Chinese MenW:cc11
solates formed a novel cc11 sublineage which was distinct from
he Hajj-strain sublineage and the South American-strain sublin-
age. Isolates from North Africa and the UK were closest to the
rigin of the Chinese subclusters. 114 , 115 Among the reported two
enX cases, 116 , 117 one was caused by ST-7 which was confirmed
o originate from ST-7 MenA by horizontal exchange of capsule
iosynthesis genes. 118 Although the first MenY case was reported
n 2016, no further information was available. In 2019, a MenY
eningitis case in a teenager was caused by cc23, which has been
he major clone in North America and some countries in Europe
as identified. 119 
ther regions 
IMD data from other regions are scarce and often outdated. 120 
here reported, IMD incidence is estimated to be well below
.0/10 0,0 0 0. 24 In Japan, IMD surveillance was initially restricted
o meningitis cases until April 2013, when meningococcal bacter-
emia also became notifiable. 121 Of the 59 IMD cases reported un-
il the end of 2014, the median age was 56 years with MenY (42%)
redominating, followed by MenC (12%), MenB (7%) and MenW
3%). Annual incidence was estimated to be 0.028/10 0,0 0 0 with a
FR of was 19%. Whilst all the evidence indicates that IMD is rare
n Asia, 122 the reported incidence rates are likely to be significantly
nderestimated because of many reasons, including restricted case
efinitions for surveillance, inconsistent diagnostic testing practice,
ntibiotic overuse in the community and the passive nature of the
urveillance, which are common problems across Asia. 120 , 123 Re-
ent data from the Indian subcontinent are also unavailable, re-
tricted mainly to local outbreaks and epidemics, which occur with
egular frequency. 124 In India, however, there have been increas-
ng reports of IMD outbreaks since 2005, mainly affecting ado-
escents and young adults, and due to MenA. 124 , 125 Whilst cur-
ent surveillance data are not readily available, N. meningitidis has
een reported as a cause of bacterial meningitis in Pakistan. 126 and
angladesh. 127 , 128 
In summary, much of the data on IMD comes from China
here regional surveillance studies frequently identify substan-
ially higher IMD incidence compared to national notifications.
lsewhere, current data indicate that IMD incidence is very low, al-
hough unlikely to be as low as reported estimates because of the
easons already highlighted. On-going syndromic and laboratory-
ased regional and national surveillance will be important for
dentifying any increase in IMD in the future. 
ustralasia 
ustralia 
In Australia, IMD is nationally notifiable and includes
aboratory-confirmed cases and probable cases requiring clini-
al evidence only. 129 , 130 ; quarterly updates are provided online. 131 
MD notifications declined after MenC conjugate vaccine imple-
entation in 2003 but gradually increased from 2013 to 2017
1.5/10 0,0 0 0). 132 During 20 02-15, MenB was responsible for
ost IMD cases; since then MenW became the predominant
erogroup. 133 In 2017, a MenW outbreak (141 cases in 2017
ompared to 34 in 2015) mostly involving young Aboriginal and
orres Strait Islander children within their communities in Central
ustralia affecting parts of the Northern Territory (NT), South
ustralia (SA), Western Australia (WA) and Queensland (QLD)
rompted the introduction of state-funded MenACWY programmes
cross Australia except SA, 134 where MenB disease continues to
redominate. MenACWY vaccine replaced MenC vaccination at 12onths of age from July 2018 and is offered to 14-16 year-olds
hrough a school-based program since April 2019. MenY cases
ave also increased since 2011, with 75 cases accounting for 19%
f notifications in 2017 compared with 40, 22 and 12 in the
revious three years. 133 In 2018, there were 281 IMD cases in 2018
ith reductions in both MenW (100 cases) and MenY (45 cases)
isease. 133 
Most MenB cases over the past few decades have been caused
y the New Zealand epidemic strain CC41/45: PorA 1.7,2.4. 135-138 
n 2016, 92% of MenW isolates had the P1.5,2 PorA antigen and, of
hese, 72% were MenW:cc11 belonging to the South American-UK
train. 130 , 139 Like Europe, infants had the highest IMD incidence,
ollowed by toddlers and adolescents aged 15–19 years. 132 IMD in-
idence was higher in Aboriginal and Torres Strait Islander chil-
ren aged 0-4 years (21.3 vs. 4.3/10 0,0 0 0)) and 5-9 years (5.4 vs.
.8/10 0,0 0 0) compared to non-Indigenous children. 133 MenB pre-
ominated in < 5 and 15–19 year-olds, 137 , 138 , 140 whereas MenW
redominated among ≥45 year-olds. 141 In 2018, IMD notifications
ropped from 380 to 281 cases with MenB representing 42% and
enW 36% of all cases. 133 
Significant differences in meningococcal serogroup and genetic
iversity exist between Australian states. The increase in MenW
ases varied between states, with the largest increases in Victo-
ia (VIC) and WA. 130 , 141 In SA, MenB caused 79% of all IMD in
018. 133 , 142 and most cases were due to the New Zealand strain,
hich is covered by 4CMenB. SA became the first state to offer a
unded 4CMenB programme to all infants, young children, adoles-
ents and young adults in addition to the national MenACWY pro-
ram. 142 In other Australian states, there is more diversity in MenB
trains causing disease. The Pharmaceutical Benefits Advisory Com-
ittee recently recommended inclusion of 4CMenB vaccine in the
ational Immunisation Program for Aboriginal and Torres Strait Is-
ander infants with a catch-up program up to 2 years of age and
or any child or adult with medical conditions associated with in-
reased risk of meningococcal disease. 143 
Overall CFR was 5%. 141 , 144 , 145 and higher for MenW (10.7%)
nd MenC (9.1%) disease compared with other serogroups. 141 
enW:CC11 was associated with more severe disease and higher
FR. 33 In 2017, all 16 deaths due to MenW:cc11. 133 CFR has not
ecreased significantly despite MenC vaccine implementation and
mprovements in diagnosis and clinical management. 
ew Zealand 
In New Zealand, MenB has predominated, although outbreaks of
enA and MenC have occurred over the past few decades with an
ncrease in MenW cases recently. 146 , 147 In response to a MenB epi-
emic (B:4:P1.7b,4, ST-41/44 clonal complex) during 1999-2007, a
enB strain-specific OMV vaccine (MeNZB TM ) was developed and
mplemented nationally during 20 04-20 08. 148 This led to a reduc-
ion in notification rates from a peak of 17.4/10 0,0 0 0 to 1.2/10 0,0 0 0
n 2009. Vaccine uptake was 81% and vaccine effectiveness was
stimated to be 73-77%. 149 , 150 In 2011, a community outbreak of
enC disease occurred in northland, which was associated with a
3% CFR. 151 Since 2014, IMD incidence has been increasing nation-
lly and, although MenB predominates, an increase in MenW:cc11
ases has also contributed to this increase. 146 , 152 MenW cases in-
reased from 5 in 2016 to 33 in 2018, with a CFR of 18%. 153 
IMD in New Zealand mainly affects < 5 year-olds, with Mãori
nd Pacific people disproportionately affected. The highest IMD
ates occur in Pacific people aged < 20 years, but the highest per-
entages of cases occur in Mãori and European New Zealanders. 148 
MD incidence is also highest in the northern part of the North Is-
and of New Zealand. 154 There are no meningococcal vaccines in
he national immunisation programme, although a targeted vacci-
ation programme for MenW disease was implemented in Decem-
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e  ber 2018 for Northland children aged 9 months to 4 years and 13
-19 years. 155 In addition, MenC and MenACWY conjugate vaccines
are recommended and funded for certain high-risk groups. 156 
In summary, IMD epidemiology in Australasia reflects
other high-income countries, especially in Europe. The recent
MenW:cc11 outbreak has led to widespread implementation of
the MenACWY conjugate vaccine, and South Australia is leading
the field of MenB disease prevention with the recent introduction
of 4CMenB for infant, toddlers and adolescents. The impact of
the programme will provide useful information for policy makers
worldwide on extending the use of this novel, protein-based
vaccine to wider age groups. In New Zealand, the use of the
outbreak strain OMV vaccine during 20 04-20 08 provided reassur-
ance for many countries considering 4CMenB (which contains the
New Zealand OMV) implementation, because of the high vaccine
uptake, effectiveness and impact achieved. 
Discussion 
This review summarises the immense burden of IMD globally
and highlights the changing and dynamic epidemiology of IMD
that is intricately intertwined with local, regional and national
meningococcal immunisation programmes targeting different age-
groups and serogroups in different parts of the world at differ-
ent times. Unlike other publications, this review did not aim to
identify or document every study reported globally but, instead, to
highlight the significant studies across the different continents that
provide an insight into the current burden of disease, meningococ-
cal immunisation programmes and the potential for further pre-
vention. 
MenB is the predominant serogroup across Europe, North Amer-
ica and the Australasia, while MenC and MenW account for sub-
stantial proportions of cases across Africa, Latin America and parts
of Asia. In addition to natural fluctuations, disease trends are also
influenced by public health interventions, including prevention and
control through vaccination, which will inevitably cause significant
shifts in IMD epidemiology and serogroup distribution. IMD is also
heavily influenced by behavioral and environmental factors, includ-
ing ease of travel (globalisation), with larger and larger groups
coming together in mass gatherings, 157 , 158 classically the Hajj pil-
grimage. 159 but also other events such as the recent international
scouts jamboree. 160 
The epidemiology of IMD across the African meningitis belt, in
particular, highlights the ability of the pathogen to cause large epi-
demics, affecting millions of children and young adults. The lack of
adequate healthcare in most of the affected countries leads to high
case fatality rates and, importantly, high rates of long-term neu-
rodevelopmental sequelae among survivors. The sudden onset of
disease, initially with non-specific symptoms and signs, followed
by rapid progression of illness to death, highlights the importance
of prevention through vaccination as demonstrated by the phe-
nomenal success of the MenAfriVac programme. The emergence of
other serogroups causing IMD across the African meningitis belt,
however, reinforces the need for multivalent vaccines against all
major meningococcal serogroups. The development and licensure
of low-cost, highly immunogenic pentavalent vaccines targeting
serogroups A, C, W, X and Y is, therefore, eagerly awaited. 95 Conju-
gate vaccines not only provide direct protection for vaccinated in-
dividuals but, by preventing carriage acquisition, they can protect
the whole population (indirect or herd protection) if sufficiently
high vaccine uptake is achieved. Fortunately, MenB, for which a
conjugate vaccine is unlikely to be developed, is as yet a rare cause
of sporadic IMD, outbreaks or epidemics in the meningitis belt. 
Data on the burden of IMD in other LMICs are scarce for many
reasons, including the ease and availability of broad-spectrum an-
tibiotics in the community without appropriate diagnostic testings well as inadequate disease surveillance. 120 , 161 Sentinel surveil-
ance in many countries, however, does allow monitoring of dis-
ase trends, including any shifts or emergence of new meningo-
occal serogroups, 162 thus allowing for implementation of control
easures, such as meningococcal vaccination for appropriate age
nd risk groups. 
Many of the countries where MenB predominates have estab-
ished national immunisation programmes for one or more of the
ther meningococcal serogroups causing IMD. Until recently, the
enC conjugate vaccine was routinely used in many parts of Eu-
ope, Canada and Latin America, while other countries such as the
S, for example, have always recommended the MenACWY con-
ugate vaccine based on their local IMD epidemiology. The recent
mergence and spread of the highly-virulent MenW:cc11 strain
rom Latin America to Europe and beyond, in particular, has led
o rapid implementation of the MenACWY conjugate vaccine for
eenagers and young adults, and, in some countries, toddlers and
oung children. 163 
The recent licensure of two new protein-based MenB vaccines
ith broad coverage has provided a major boost for the fight
gainst meningococcal disease in high-income countries where this
erogroup is the main cause of IMD. In September 2015, the UK
ecame the first country to implement 4CMenB into its national
nfant immunization programme and, three years on, large reduc-
ions have been observed in vaccine-eligible cohorts. 37 After the
rst 3 million doses, too, no major safety concerns have been
dentified. 18 A few other countries and regions have now imple-
ented the vaccine into their national infant immunisation pro-
rammes, while South Australia also offers 4CMenB to toddlers and
dolescents. MenB-fHbp, on the other hand, is currently not in-
luded in any national immunization programme but has been suc-
essfully used to control university-associated MenB outbreaks. 164 
ith increasing use of these vaccines, uncertainties about their
afety, reactogenicity, effectiveness and duration of protection will
e overcome with real world evidence. 165 Current barriers to rou-
ine MenB immunisation include the very low disease incidence
nd the relatively high cost of the vaccines. Unfortunately, the lack
f impact on MenB carriage in teenagers makes 4CMenB less at-
ractive for adolescent immunisation because MenB disease inci-
ence is very low in this age group. 19 
Nonetheless, protein-based MenB vaccines hold great promise
or preventing all meningococcal disease since these protein anti-
ens may be present across all meningococci, irrespective of
erogroup. 21 , 22 These vaccines also have the potential to be
ombined with already available meningococcal conjugate vac-
ines (MenACWY) to provide broad protection against five major
erogroups that responsible for nearly all IMD globally. 95 Addition-
lly, next generation vaccines are likely to contain more meningo-
occal antigens to provide broader coverage, not only against
eningococcal disease but, since some of these antigens are also
resent on other Neisseria species, including Neisseria gonorrhea ,
hey could also help protect against gonorrhoea. 166 Given the rapid
ncrease in the incidence of gonorrhoea and increasing concerns
bout multidrug resistance, such a vaccine would become very at-
ractive for adolescents and young adults who could potentially
e protected against both IMD and gonorrhoea by the same vac-
ine. 167 
A universal meningococcal vaccine, particularly one that com-
ines the capsular polysaccharide and surface protein antigens, is
mportant because meningococci are promiscuous bacteria that are
apable not only of switching their polysaccharide capsules, but
lso of switching off capsular expression, which poses the risk of
otential vaccine evasion, as seen in recent outbreaks of meningo-
occal urethritis. 168 The meningococcus also has a propensity to
apidly acquire and discard different virulence factors and genes, as
videnced by acquisition of antibiotic resistance alleles from gono-
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 occi. 169 The ability of meningococci to acquire critical genes that
llow them to survive in anaerobic environments such as the uro-
enital and anorectal tract, and to propagate through sexual trans-
ission demonstrates their ability to adapt to hostile environments
nd external pressures. 170 
onclusions 
Meningococcal disease is stochastic and capable of causing large
utbreaks associated with severe disease and high case fatality,
s evidenced by recent epidemics in the African meningitis belt.
he MenAfriVac programme has been greatly successful in con-
rolling MenA disease but has highlighted the need for low-cost,
ultivalent meningococcal conjugate vaccines to control the ma-
or serogroups capable of causing future outbreaks and epidemics,
specially MenX, for which a vaccine is currently not available. In
igh-income countries, many with already established MenC and
enACWY immunisation programmes, MenB is the predominant
erogroup responsible for most IMD cases. Two new MenB vac-
ines with broad coverage are now available but few countries
ave opted to use them, mainly because of the low disease inci-
ence. Next generation MenB vaccines with better strain coverage,
ombined with ACWY conjugates and/or greater protection against
onorrhoea may make them more attractive for implementation
nto national immunisation programmes. 
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